Trending Topics in Gastroenterology | GastroAGI

Neoadjuvant Nivolumab–Ipilimumab in Resectable HCC- J Hepatol Feb.26

Immune checkpoint inhibitors have transformed the treatment of advanced hepatocellular carcinoma (HCC), but their role in potentially resectable disease remains under active investigation. This single-arm study evaluated nivolumab plus ipilimumab as neoadjuvant therapy, followed by surgery when feasible, and explored biological markers associated with treatment response. Patients with potentially resectable HCC received combination immunotherapy before reassessment for curative surgery. Nearly half of the treated patients ultimately underwent resection, demonstrating the feasibility of integrating dual immune checkpoint blockade into a perioperative strategy. Importantly, a meaningful proportion of resected tumours showed major pathological response, indicating deep antitumor activity prior to surgery. Long-term follow-up revealed encouraging progression-free and overall survival, suggesting that this approach may translate into durable clinical benefit. Beyond clinical outcomes, the study provides important mechanistic insights. Tumours responding to immunotherapy showed increased interferon-γ signalling and formation of tertiary lymphoid structures (TLS), specialised immune aggregates that support sustained antitumor immunity. Preclinical experiments confirmed that B cells are critical for the efficacy of combined PD-1 and CTLA-4 blockade, reinforcing the functional relevance of TLS. Additionally, profiling of peripheral blood demonstrated that patterns of T-cell activation and exhaustion, assessed with advanced flow cytometry and computational analysis, correlated with response and survival. In summary, neoadjuvant nivolumab plus ipilimumab followed by surgery is feasible and may offer long-term benefit in selected patients with resectable HCC. The identification of TLS and peripheral immune signatures highlights promising biomarkers to guide patient selection and future perioperative immunotherapy strategies.

Lenvatinib After Atezolizumab–Bevacizumab Failure in Advanced HCC- J Hepatol Feb.26

Atezolizumab plus bevacizumab is the established first-line treatment for unresectable hepatocellular carcinoma (HCC). However, most patients eventually progress, and the optimal second-line therapy after atezo-bev failure remains uncertain, with limited prospective data to guide clinical decisions. This multicenter, investigator-initiated phase II trial evaluated lenvatinib as a second-line treatment in patients with unresectable HCC who had progressed on first-line atezo-bev. Patients received weight-based oral lenvatinib until disease progression or unacceptable toxicity. The study focused on progression-free survival as the primary endpoint, with overall survival, tumor response, and safety as secondary outcomes. The study demonstrated that lenvatinib provides meaningful disease control in the post–atezo-bev setting. Progression-free survival exceeded the predefined efficacy threshold, and overall survival outcomes were clinically relevant in a population with limited therapeutic options. Tumor responses were modest but durable in responders, and disease stabilization was achieved in the majority of patients. Importantly, outcomes were driven by response to lenvatinib itself rather than prior response duration to atezo-bev or underlying disease etiology. The safety profile was consistent with known effects of lenvatinib and was generally manageable with dose modifications and supportive care, despite a substantial rate of higher-grade adverse events. In summary, this study provides the first prospective evidence supporting lenvatinib as a viable second-line option after atezolizumab–bevacizumab failure in advanced HCC, helping to define a treatment pathway in a rapidly evolving therapeutic landscape.

HBV Reactivation Risk With ICIs vs TKIs in Liver Cancer

Hepatitis B virus (HBV) reactivation is a recognized risk during systemic therapy for liver cancer, particularly in high-endemic regions where HBV is a leading cause of hepatocellular carcinoma (HCC). The comparison of HBV reactivation risk between immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) is a critical area of investigation. ### Key Findings on HBV Reactivation Risk: 1. **No Excess Risk With ICIs Compared to TKIs**: - Studies indicate that the use of ICIs does not increase the risk of HBV reactivation compared to TKIs, which are widely used systemic therapies for advanced liver cancer. This suggests that ICIs are as safe as TKIs in terms of HBV reactivation risk when proper prophylactic measures are employed. 2. **Consistency Across ICI Regimens**: - Different types of ICIs, such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 therapies, show similar profiles regarding HBV reactivation risk. This consistency highlights the general safety of ICIs in HBV-endemic populations under routine antiviral prophylaxis. 3. **Low Overall Reactivation Risk**: - Routine antiviral prophylaxis significantly reduces HBV reactivation risk across both ICIs and TKIs. However, while prophylaxis is protective, it does not completely eliminate the risk, necessitating ongoing surveillance. 4. **Mechanistic Considerations**: - ICIs theoretically raise concerns for HBV reactivation due to their immunological effects, such as enhancing immune responses that could impact latent HBV reservoirs in liver cells. Despite this, real-world evidence does not show an increased reactivation risk compared to TKIs. 5. **Patients With Past HBV Infection**: - Individuals with resolved HBV infection (negative HBV surface antigen but positive HBV core antibody) are more vulnerable to reactivation than those with active infection. This is due to the persistence of latent viral reservoirs in liver cells, which can be triggered under immunotherapy. 6. **Antiviral Prophylaxis**: - Preventive antiviral therapy is essential for reducing HBV reactivation risk in patients receiving systemic therapy for liver cancer. However, antiviral prophylaxis is less consistently prescribed for patients with past HBV infection, leaving them at higher risk. 7. **Role of Surveillance**: - Even with antiviral prophylaxis, ongoing monitoring of HBV DNA and liver function is necessary to detect reactivation early and manage potential complications. 8. **Impact of Prior Liver Procedures**: - Patients who have undergone transarterial chemoembolization (TACE) or other invasive liver procedures may have increased susceptibility to HBV reactivation during systemic therapy, regardless of whether they are on ICIs or TKIs. ### Clinical Implications: - Systematic HBV screening is critical before initiating ICIs or TKIs in patients with liver cancer, particularly in HBV-endemic regions. - Proactive antiviral prophylaxis should be implemented for all patients at risk, including those with resolved HBV infection, to minimize reactivation risk. - Regular surveillance of HBV DNA and liver enzymes is essential for detecting reactivation or immune-related liver toxicity during therapy. ### Conclusion: Under routine antiviral prophylaxis, ICIs do not pose an excess risk of HBV reactivation compared to TKIs for liver cancer treatment. However, patients with past HBV infection and those with a history of liver procedures require heightened vigilance due to their increased susceptibility. Comprehensive screening, prophylaxis, and surveillance are key to safe and effective management of HBV reactivation risk during systemic therapy in HCC.

CARES-009 phase 2/3 trial

The CARES-009 phase 2/3 trial investigated the efficacy of perioperative camrelizumab plus rivoceranib in patients with hepatocellular carcinoma (HCC) at intermediate or high risk of relapse. The trial aimed to determine whether combining immunotherapy and targeted therapy before and after surgery could improve outcomes compared to surgery alone. In the study, 294 patients were randomly assigned to two groups: one receiving perioperative therapy (neoadjuvant and adjuvant camrelizumab plus rivoceranib) and the other undergoing surgery alone. Results showed that patients in the perioperative therapy group had significantly improved event-free survival (EFS) with a median of 42.1 months compared to 19.4 months in the surgery-alone group (HR 0.59, p=0.0040). However, adverse events of grade 3 or higher occurred in 38% of patients receiving perioperative therapy, including two treatment-related deaths during neoadjuvant therapy. This trial highlights the potential benefits of perioperative immunotherapy but underscores the importance of managing associated risks.

Recurrent HCC followingTACE

Recurrent hepatocellular carcinoma (HCC) following transarterial chemoembolisation (TACE) is a significant clinical challenge. TACE is widely used as a treatment modality for HCC, particularly for patients with intermediate-stage disease or as an adjuvant therapy after curative resection to target residual microscopic disease. However, recurrence remains a common issue, and understanding the factors contributing to recurrence, as well as strategies for managing recurrent HCC, is essential for improving patient outcomes. ### Factors Contributing to Recurrence Following TACE: 1. **Tumour Biology**: Aggressive tumour characteristics, such as poor differentiation, vascular invasion, or high alpha-fetoprotein (AFP) levels, are associated with a higher risk of recurrence. 2. **Incomplete Tumour Necrosis**: TACE relies on selective embolisation of tumour-feeding arteries, but incomplete necrosis of the tumour may leave residual viable cancer cells that can proliferate. 3. **Micrometastases**: Occult micrometastases that are not detectable at the time of initial treatment can lead to recurrence. 4. **Liver Function**: Patients with compromised liver function (e.g., cirrhosis) may have a higher risk of recurrence due to reduced ability to tolerate treatment and impaired immune surveillance. 5. **TACE Technique**: Variability in the technical execution of TACE, such as insufficient embolisation or suboptimal drug delivery, can contribute to recurrence. ### Patterns of Recurrence: Recurrent HCC after TACE can manifest as: - **Intrahepatic Recurrence**: New tumour nodules within the liver, either near the original site or in different segments of the liver. - **Extrahepatic Metastasis**: Spread to distant organs, such as lungs, bones, or lymph nodes, which is less common but associated with worse prognosis. ### Management of Recurrent HCC Following TACE: 1. **Repeat TACE**: - Patients with recurrent HCC confined to the liver may benefit from repeat TACE, provided liver function is preserved and the tumour burden remains manageable. - The interval between TACE sessions and the patient's tolerance to treatment should be considered. 2. **Systemic Therapy**: - Targeted therapies such as sorafenib, lenvatinib, or other tyrosine kinase inhibitors (TKIs) may be used for patients with advanced or recurrent HCC. - Immunotherapy with immune checkpoint inhibitors (e.g., atezolizumab plus bevacizumab) has emerged as a promising option for recurrent HCC. 3. **Surgical Resection**: - If the recurrence is localized and the patient is a suitable surgical candidate, re-resection may be considered. - This option is typically reserved for patients with good liver function and limited tumour burden. 4. **Liver Transplantation**: - In cases of recurrent HCC meeting Milan or UCSF criteria, liver transplantation may offer a curative option, particularly for patients with underlying cirrhosis. 5. **Ablative Therapies**: - Techniques such as radiofrequency ablation (RFA) or microwave ablation (MWA) may be used for small, localized recurrent tumours. 6. **Combination Approaches**: - Combining locoregional therapies (e.g., TACE plus RFA) or systemic therapies with TACE may enhance outcomes and reduce recurrence rates. ### Prognostic Tools and Risk Stratification: To guide management decisions, predictive models and tools, such as the online calculator mentioned in the context, can be used to estimate recurrence risk and tailor treatment strategies. These tools integrate tumour-related factors, surgical details, and patient characteristics to provide personalised recommendations. ### Preventive Strategies: 1. **Optimising TACE Protocols**: Ensuring adequate embolisation and drug delivery during the initial TACE procedure can reduce the risk of recurrence. 2. **Adjuvant Therapies**: In high-risk patients, adjuvant therapies such as systemic agents or combination locoregional treatments may be considered to prevent recurrence. 3. **Surveillance**: Regular imaging and AFP monitoring post-TACE are critical for early detection and management of recurrence. ### Conclusion: Recurrent HCC following TACE is a complex issue influenced by tumour biology, treatment efficacy, and patient factors. Management requires a multidisciplinary approach, incorporating locoregional therapies, systemic treatments, and predictive tools to optimise outcomes. Advances in risk stratification and treatment modalities hold promise for reducing recurrence and improving survival in patients with HCC.

Nutrition in Hepatocellular Carcinoma - J of JGH - Jan,26

The topic of nutrition in hepatocellular carcinoma (HCC) is highly relevant and extensively studied due to the profound impact of malnutrition on patient outcomes. While I cannot access specific articles such as "Nutrition in Hepatocellular Carcinoma - J of JGH - Jan, 26," I can provide a detailed overview based on the context and current knowledge related to nutrition in HCC. **Overview of Nutrition in Hepatocellular Carcinoma (HCC):** 1. **Prevalence of Malnutrition**: - Malnutrition is exceedingly common in patients with HCC, significantly contributing to morbidity, mortality, and poor clinical outcomes. - Unlike other cancers, malnutrition in HCC often begins early in the disease course due to the compounding effects of chronic liver disease. 2. **Drivers of Nutritional Decline**: - **Hepatic Dysfunction**: Chronic liver disease and cirrhosis associated with HCC disrupt carbohydrate, protein, and lipid metabolism, leading to a hypercatabolic state. - **Insulin Resistance**: Impaired glycogen storage and early gluconeogenesis result in muscle breakdown and energy imbalance. - **Protein Catabolism**: Negative nitrogen balance and preferential skeletal muscle degradation accelerate sarcopenia. - **Impaired Fat Absorption**: Cholestasis and reduced bile acid synthesis hinder fat absorption, resulting in energy deficits and fat-soluble vitamin deficiencies. - **Micronutrient Deficiencies**: Vitamins A, D, E, K, and trace element deficiencies contribute to complications like coagulopathy, bone disease, and neuromuscular dysfunction. 3. **Key Features of Malnutrition in HCC**: - **Sarcopenia**: Loss of skeletal muscle mass is a hallmark feature in HCC patients and independently predicts poorer survival, higher complication rates, and reduced tolerance to treatments. - **Cachexia**: Chronic systemic inflammation drives anorexia, hypermetabolism, and cancer-related cachexia, further worsening nutritional status. - **High Energy Expenditure**: Many patients with HCC exhibit increased resting energy expenditure, exacerbating the gap between nutritional intake and metabolic demands. 4. **Prognostic Implications**: - Malnutrition and sarcopenia are strongly associated with reduced overall survival, increased recurrence rates, and higher postoperative risks. - Addressing nutritional deficits early and comprehensively can improve clinical outcomes. 5. **Assessment of Nutritional Status**: - **Validated Screening Tools**: Tools such as NRS-2002, MUST, PG-SGA, and GLIM are essential for identifying patients at nutritional risk. - **Muscle Mass Evaluation**: CT imaging at the L3 vertebra is a gold-standard method for assessing skeletal muscle mass. - **Functional Status**: Handgrip strength provides a practical measure of muscle function and complements structural assessments. - **Limitations of Laboratory Markers**: Serum albumin and prealbumin are unreliable indicators due to hepatic dysfunction and systemic inflammation. 6. **Nutritional Management**: - **Individualized Targets**: Energy and protein requirements should be tailored to the disease stage, severity of cirrhosis, and treatment modalities. - **Oral Nutritional Supplements**: Supplements enriched with branched-chain amino acids are beneficial for maintaining protein balance and improving clinical outcomes. - **Enteral Nutrition**: Preferred over parenteral nutrition if gastrointestinal function is preserved. - **Exercise**: Resistance and aerobic exercise programs help mitigate sarcopenia and functional decline when integrated with nutritional support. - **Multidisciplinary Care**: Coordinated care involving hepatologists, oncologists, dietitians, and physiotherapists is essential for optimal management. 7. **Emerging Research and Guidelines**: - The field continues to evolve with ongoing research into the role of specific nutrients, exercise regimens, and novel interventions to address malnutrition and sarcopenia in HCC. - Journals like the "Journal of Gastroenterology and Hepatology" (JGH) often publish cutting-edge studies and guidelines on this topic. If you are looking for specific insights or findings from the January 26 article in JGH, I recommend accessing the journal directly through medical databases such as PubMed, Wiley Online Library, or institutional subscriptions. Let me know if you'd like guidance on how to access such resources!

Engineered T-Cell Therapy and HCC - J of Hepatology. Jan 26

Engineered T-cell therapy is a precision immunotherapy approach designed to treat cancer by modifying a patient's T cells to enhance their ability to target and destroy cancer cells. This therapy involves genetic engineering of T cells to recognize tumor-associated antigens (TAAs) and improve their survival and function in the body. The most successful example of engineered T-cell therapy is chimeric antigen receptor-T cell (CAR-T) therapy, which has shown remarkable efficacy in treating hematological malignancies like refractory B-cell lymphoma/leukemia and multiple myeloma. ### Basis of Engineered T-cell Therapy in Hepatocellular Carcinoma (HCC) Hepatocellular carcinoma (HCC) is a challenging cancer to treat using engineered T-cell therapy due to the complexities of solid tumors. These challenges include: 1. **Lack of Suitable Tumor-Associated Antigens:** Unlike hematological malignancies, HCC lacks well-defined and universally expressed TAAs that can be targeted effectively. 2. **Tumor Microenvironment:** HCC tumors create an immunosuppressive microenvironment characterized by hypoxia, immunosuppressive cells, and cytokines, which hinder T-cell activity. 3. **Tumor Stroma:** The dense stroma within solid tumors obstructs effective trafficking of T cells to the tumor site. ### Alpha-Fetoprotein (AFP) Targeting TCR-T Therapy in HCC In a clinical trial reported by Meyer et al., researchers explored T-cell receptor (TCR)-T therapy targeting alpha-fetoprotein (AFP), a protein expressed in some HCC tumors. This therapy used ADP-A2AFP cells, which are engineered T cells designed to recognize AFP complexed with HLA-A*02:01. The trial enrolled 21 patients with AFP-expressing advanced solid tumors (20 with advanced HCC and 1 with gastric hepatoid carcinoma). The treatment involved lymphodepleting chemotherapy followed by infusion of the engineered T cells. ### Key Findings from the Trial: 1. **Safety and Adverse Events:** - Dose-limiting toxicity was observed in one patient (grade 4 atrial fibrillation), who later died due to cholangitis unrelated to the therapy. - Cytokine release syndrome (CRS) occurred in six patients, with one experiencing severe grade 4 CRS. - Grade 3-4 leukopenia was observed in 10 patients, likely due to the lymphodepleting chemotherapy. 2. **Efficacy:** - The overall response rate was 9.5%, with one complete responder and one partial responder. - The trial highlighted difficulties in achieving satisfactory efficacy, partly due to variability in AFP expression among tumors and challenges in patient enrollment. 3. **Challenges:** - Enrollment was limited due to the specific HLA haplotype required for the therapy and safety concerns associated with lymphodepleting chemotherapy in patients with cirrhosis. - The prolonged time required for screening and cell preparation meant that only patients with slower tumor progression could participate. ### Lessons Learned and Future Directions: 1. **Tumor-Associated Antigen Variability:** The variability of AFP expression in tumors complicates the correlation between antigen expression and treatment efficacy. More precise diagnostic tools are needed to select patients who are likely to benefit from therapy. 2. **Improving T-cell Design:** Novel T-cell constructs or higher cell doses may enhance efficacy while maintaining safety. 3. **Targeting Multiple Antigens:** Engineering T cells to target multiple TAAs could improve specificity and reduce resistance due to antigen escape. 4. **Overcoming Tumor Microenvironment:** Strategies like incorporating interleukin-15 constructs or dominant-negative transforming growth factor-β receptors into CAR-T cells have shown promise in overcoming the immunosuppressive tumor microenvironment of HCC. 5. **Patient Selection:** T cells from less heavily pretreated patients may exhibit higher antitumor activity, and the phenotypes of engineered T cells should be optimized for trafficking and cytotoxicity. ### Advances in Engineered T-cell Therapy for Solid Tumors: While engineered T-cell therapy for hematological malignancies has been highly successful, progress in treating solid tumors like HCC has been slower. Recent trials targeting glypican 3 (a membranous glycoprotein expressed in HCC) using CAR-T therapy have demonstrated promising antitumor activity and acceptable safety profiles. For example: - CAR-T cells engineered with interleukin-15 constructs improved T-cell survival and function. - CAR-T cells with dominant-negative transforming growth factor-β receptors helped overcome the immunosuppressive tumor microenvironment. ### Conclusion: The clinical trial by Meyer et al. represents an important effort to develop precision immunotherapy for HCC. Although the efficacy of ADP-A2AFP therapy was limited, the study provides valuable insights into the challenges and opportunities in engineered T-cell therapy for HCC. Advances in cell engineering technologies and a better understanding of the interactions between engineered T cells, cancer cells, and the tumor microenvironment will be critical to driving progress in this field.

Serum N-Glycomics analysis and HBV - Hepatology Jan.2026

Serum N-glycomics analysis refers to the study of N-linked glycans (complex sugar molecules attached to proteins) present in serum. This analytical approach focuses on profiling and identifying specific glycan structures that may be associated with various diseases, including hepatocellular carcinoma (HCC) linked to chronic hepatitis B virus (HBV) infection. N-glycomics analysis uses advanced techniques such as mass spectrometry and machine learning to quantify and characterize glycan patterns in biological samples. ### How N-glycomics Analysis Helps in HCC Diagnosis in HBV Infection: 1. **Enhanced Sensitivity and Specificity**: - Traditional diagnostic markers for HCC, such as alpha-fetoprotein (AFP) and Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II), often lack sufficient sensitivity and specificity, particularly in early-stage HCC detection. - N-glycomics analysis identifies unique glycan profiles associated with HCC, providing more accurate diagnostic models. In the study, machine learning-based models (Random Forest and Support Vector Machine) demonstrated significantly higher diagnostic accuracy with AUC values of 0.967 and 0.908, compared to AFP (0.687) and PIVKA-II (0.665). 2. **Early Detection of HCC**: - N-glycomics models can detect HCC earlier than imaging techniques, which is crucial for timely intervention and improving patient outcomes. - The study showed that the N-glycomics-based diagnostic models outperformed conventional markers in subgroup analyses and external validation, making them highly reliable for early screening. 3. **Prognostic Value**: - Beyond diagnosis, N-glycomics analysis aids in monitoring disease progression and recurrence. The prognostic model (prog-G) developed in the study was able to predict recurrence in patients with HCC after curative treatment. - During follow-up, the prog-G model identified all recurrent HCC cases before imaging findings, outperforming AFP and PIVKA-II. This capability allows for earlier therapeutic intervention to manage recurrence. 4. **Precision Medicine**: - By leveraging N-glycomics profiling, clinicians can make more informed decisions tailored to individual patients. This promotes precision treatment strategies for HCC in HBV-infected individuals, improving overall clinical outcomes. 5. **Non-Invasive and Scalable**: - Serum N-glycomics analysis is a non-invasive diagnostic method, making it suitable for routine clinical use and large-scale screening of at-risk populations, including those with chronic HBV-related cirrhosis. ### Conclusion: Serum N-glycomics analysis represents a promising advancement in the diagnosis and management of HCC in patients with HBV infection. By providing highly sensitive and specific models for early detection and recurrence monitoring, it addresses the limitations of conventional markers like AFP and PIVKA-II. The integration of N-glycomics into clinical practice has the potential to improve decision-making, enhance precision treatment, and ultimately reduce the global health burden of HBV-related HCC.

HCC risk in PSC (Hepatology Jan. 26)

Introduction: Primary sclerosing cholangitis (PSC) is a chronic liver disease that can lead to complications, including hepatocellular carcinoma (HCC). However, the actual risk of developing HCC in PSC patients has been unclear, leading to questions about the necessity of current HCC surveillance guidelines. Problem Statement: A study involving 3071 PSC patients across 12 university hospitals was conducted to better understand the risk of HCC. Patients were followed for an average total of 38,387 person-years, from PSC diagnosis until death, liver transplantation, or other significant events. The study aimed to identify factors associated with HCC development, such as age and cirrhosis status, to refine surveillance strategies. Conclusion: The study found that HCC is relatively rare in PSC patients, especially in those without cirrhosis and under the age of 50. Cirrhosis was a significant risk factor for HCC, with most cases occurring in cirrhotic patients. Age also increased the risk, but for non-cirrhotic patients, the risk remained low across all age groups. These findings suggest that HCC surveillance in PSC patients can be tailored based on individual risk factors like age and cirrhosis status, potentially reducing unnecessary monitoring in low-risk groups.

MASLD and HCC

Metabolic dysfunction–associated steatotic liver disease (MASLD) and hepatocellular carcinoma (HCC) are closely interconnected, with MASLD emerging as a significant risk factor and contributor to the development of HCC. Below is a detailed explanation of MASLD and its relationship with HCC: ### **Understanding MASLD** MASLD is the most common chronic liver disease globally, affecting over a billion people. It was previously referred to as non-alcoholic fatty liver disease (NAFLD), but the terminology has been updated to better reflect the metabolic dysfunctions associated with the condition. MASLD is characterized by the accumulation of fat in liver cells (steatosis) in individuals who do not consume excessive alcohol and who have at least one of five cardiometabolic risk factors, such as: - Obesity - Type 2 diabetes mellitus (T2DM) - Hypertension - Dyslipidemia - Insulin resistance MASLD progresses through several stages: 1. **Simple steatosis**: Fat accumulation in the liver without significant inflammation or damage. 2. **Metabolic dysfunction–associated steatohepatitis (MASH)**: A more severe form of MASLD marked by inflammation, liver cell injury (ballooning), and fibrosis. MASH can lead to cirrhosis. 3. **Cirrhosis**: Advanced scarring of the liver, which impairs liver function and increases the risk of complications. 4. **Hepatocellular carcinoma (HCC)**: The most serious complication, MASLD-related liver cancer, which can occur with or without cirrhosis. ### **HCC Overview** HCC is the most common type of primary liver cancer and represents the fifth most common cancer globally. It is also the second leading cause of cancer-related deaths worldwide. HCC can develop due to chronic liver diseases such as MASLD, viral hepatitis (HBV, HCV), alcoholic liver disease, and autoimmune liver conditions. ### **MASLD as a Driver of HCC** MASLD is increasingly recognized as a major contributor to HCC due to the global rise in metabolic disorders such as obesity and T2DM. Key aspects include: 1. **Epidemiology**: - MASLD is rapidly becoming the leading indication for liver transplantation among patients listed for HCC. - Studies from the USA, Europe, South Korea, and Southeast Asia show that MASLD is the fastest-growing cause of HCC. 2. **Risk Factors**: - Obesity and T2DM are significant drivers of MASLD progression to HCC. - Advanced age, male sex, and Latino/Latina ethnicity are associated with higher risks of MASLD progression and HCC development. 3. **Pathogenesis**: - Chronic inflammation, oxidative stress, and metabolic dysfunction in MASLD contribute to DNA damage, genetic mutations, and liver cell proliferation, which can ultimately lead to HCC. - Unlike other causes of HCC, MASLD-HCC can develop without cirrhosis in 36.6%–54.0% of cases, complicating early detection and treatment. ### **Challenges in Diagnosis and Management** 1. **Early Detection**: - Diagnosing MASLD and MASLD-related HCC (MASLD-HCC) in the early stages is challenging, particularly in patients without cirrhosis. - Current screening strategies for MASLD patients at risk of HCC are still under debate, and there is no universal consensus on optimal approaches. 2. **Risk Evaluation**: - Assessing the risk of MASLD progression to HCC requires identifying high-risk patients based on metabolic factors, liver fibrosis, and genetic predispositions. - Advanced imaging techniques and biomarkers are being explored for early detection, but their implementation in clinical practice remains limited. 3. **Therapeutic Challenges**: - MASLD-HCC treatment is highly complex due to the multifactorial nature of the disease and its pathogenesis. - While therapies such as liver transplantation, surgical resection, and systemic treatments (e.g., immunotherapy, targeted therapy) are available, their effectiveness can vary depending on the stage of HCC and the presence of underlying metabolic dysfunctions. - Preventive strategies, including lifestyle modifications (e.g., weight loss, exercise, and dietary changes), are crucial in managing MASLD and reducing the risk of HCC. ### **Current Advancements** Recent research focuses on improving early detection and risk stratification for MASLD and MASLD-HCC patients. Key advancements include: - **Biomarkers**: Identifying molecular and genetic markers to predict MASLD progression and HCC risk. - **Imaging**: Enhanced imaging techniques such as MRI elastography and contrast-enhanced ultrasound for non-invasive liver fibrosis assessment. - **Therapeutics**: Development of novel drugs targeting metabolic pathways, inflammation, and fibrosis in MASLD, which may help prevent progression to HCC. ### **Conclusion** MASLD is a rapidly emerging cause of HCC due to the global increase in metabolic disorders such as obesity and T2DM. Early detection, risk evaluation, and effective management of MASLD are critical to preventing progression to HCC and improving patient outcomes. However, challenges remain in diagnosing MASLD-HCC, particularly in patients without cirrhosis, and in developing optimal therapeutic strategies. Continued research and advancements in screening, biomarkers, and targeted therapies are essential to address the growing burden of MASLD-related HCC.